01 November 2021: Human Study
Prevalence of Hepatitis B and C Virus Infections: Influence of National Health Care Policies and Local Clinical Practices
Veeravan Lekskulchai ACDEF*DOI: 10.12659/MSMBR.933692
Med Sci Monit Basic Res 2021; 27:e933692
Table 3 Positivity of anti-hepatitis B surface antibody (anti-HBs Ab), hepatitis B surface antigen (HBsAg), and anti-hepatitis C virus antibody (anti-HCV Ab).*
| Positive test | Year | Total | ||
|---|---|---|---|---|
| 2016 | 2017 | 2018 | ||
| Anti-HBs Ab | ||||
| Male (N) | 366 | 286 | 149 | 801 |
| Age range, y | 1–90 | 1–94 | 1–88 | 1–94 |
| Age, mean (SD) | 51.24 (17.51) | 48.32 (17.25) | 40.89 (21.22) | 48.27 (18.53) |
| Female (N) | 446 | 413 | 225 | 1084 |
| Age range, y | 2–89 | 1–90 | 1–97 | 1–97 |
| Age, mean (SD) | 48.14 (14.96) | 44.01 (17.81) | 34.49 (19.58) | 43.73 (17.82) |
| HBsAg | ||||
| Male, N (%) | 120 (9%) | 110 (9%) | 101 (10%) | 331 (9%) |
| Age range, y | 20–81 | 21–85 | 24–81 | 20–85 |
| Age, mean (SD) | 48.98 (12.97) | 46.96 (13.87) | 52.18 (12.85) | 50.43 (13.48) |
| Female, N (%) | 133 (4%) | 132 (4%) | 80 (3%) | 345 (4%) |
| Age range, y | 17–85 | 18–89 | 20–85 | 17–89 |
| Age, mean (SD) | 42.29 (12.97) | 44.93 (16.29) | 42.58 (13.79) | 43.46 (14.53) |
| Anti-HCV Ab | ||||
| Male, N (%) | 49 (6%) | 44 (5%) | 55 (6%) | 148 (6%) |
| Age range, y | 21–82 | 22–76 | 17–80 | 17–82 |
| Age, mean (SD) | 49.39 (10.10) | 51.64 (11.54) | 52.33 (11.91) | 51.15 (11.23) |
| Female, N (%) | 26 (4%) | 14 (2%) | 20 (3%) | 60 (3%) |
| Age range, y | 18–87 | 39–89 | 20–80 | 18–89 |
| Age, mean (SD) | 55.54 (19.09) | 60.00 (14.40) | 57.50 (15.97) | 57.23 (16.89) |
| * Counting each case once at the first year of admission during 2016 to 2018. | ||||